Ppd Pharmaceutical Development India Profile
Key Indicators
- Authorised Capital ₹ 3.15 Cr
- Paid Up Capital ₹ 0.36 M
- Company Age 20 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 32.53%
- Profit Growth 16.14%
- Ebitda 66.15%
- Net Worth 31.00%
- Total Assets 11.61%
About Ppd Pharmaceutical Development India
Ppd Pharmaceutical Development India Private Limited (PPDIPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 10 February 2004 and has a history of 20 years and 11 months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.15 Cr and a paid-up capital of Rs 0.36 M, as per Ministry of Corporate Affairs (MCA) records.
Hemant Shah and Rashmi Chitgupi serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U73100MH2004PTC144454
-
Company No.
144454
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
10 Feb 2004
-
Date of AGM
29 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Ppd Pharmaceutical Development India?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rashmi Chitgupi
|
Director | 16-Oct-2020 | Current |
|
Hemant Shah
|
Director | 18-Aug-2020 | Current |
Financial Performance of Ppd Pharmaceutical Development India.
Ppd Pharmaceutical Development India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 32.53% increase. The company also saw a substantial improvement in profitability, with a 16.14% increase in profit. The company's net worth Soared by an impressive increase of 31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ppd Pharmaceutical Development India?
In 2023, Ppd Pharmaceutical Development India had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ppd Pharmaceutical Development India?
Ppd Pharmaceutical Development India has a workforce of 1674 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ppd Pharmaceutical Development India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ppd Pharmaceutical Development India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
